当前位置: X-MOL 学术Contrast Media Mol. Imaging › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models.
Contrast Media & Molecular Imaging Pub Date : 2019-09-22 , DOI: 10.1155/2019/8946729
M F Fiordelisi 1 , L Auletta 1 , L Meomartino 2 , L Basso 1 , G Fatone 3 , M Salvatore 1 , M Mancini 4 , A Greco 2, 4, 5
Affiliation  

Precision and personalized medicine is gaining importance in modern clinical medicine, as it aims to improve diagnostic precision and to reduce consequent therapeutic failures. In this regard, prior to use in human trials, animal models can help evaluate novel imaging approaches and therapeutic strategies and can help discover new biomarkers. Breast cancer is the most common malignancy in women worldwide, accounting for 25% of cases of all cancers and is responsible for approximately 500,000 deaths per year. Thus, it is important to identify accurate biomarkers for precise stratification of affected patients and for early detection of responsiveness to the selected therapeutic protocol. This review aims to summarize the latest advancements in preclinical molecular imaging in breast cancer mouse models. Positron emission tomography (PET) imaging remains one of the most common preclinical techniques used to evaluate biomarker expression in vivo, whereas magnetic resonance imaging (MRI), particularly diffusion-weighted (DW) sequences, has been demonstrated as capable of distinguishing responders from nonresponders for both conventional and innovative chemo- and immune-therapies with high sensitivity and in a noninvasive manner. The ability to customize therapies is desirable, as this will enable early detection of diseases and tailoring of treatments to individual patient profiles. Animal models remain irreplaceable in the effort to understand the molecular mechanisms and patterns of oncologic diseases.

中文翻译:

乳腺癌小鼠模型中精确医学的临床前分子成像。

精确和个性化医学在现代临床医学中正变得越来越重要,因为它旨在提高诊断的精确度并减少随之而来的治疗失败。在这方面,在用于人体试验之前,动物模型可以帮助评估新颖的成像方法和治疗策略,并可以帮助发现新的生物标记。乳腺癌是全世界女性中最常见的恶性肿瘤,占所有癌症病例的25%,每年造成约500,000例死亡。因此,重要的是要确定准确的生物标记物,以便对患病的患者进行准确分层,并及早发现对所选治疗方案的反应性。这篇综述旨在总结乳腺癌小鼠模型中临床前分子成像的最新进展。正电子发射断层扫描(PET)成像仍然是用于评估体内生物标志物表达的最常见的临床前技术之一,而磁共振成像(MRI),尤其是扩散加权(DW)序列,已被证明能够区分反应者和非反应者。用于传统疗法和创新性化学疗法和免疫疗法,并且具有高灵敏度且以非侵入方式进行。定制疗法的能力是理想的,因为这将使疾病的早期检测和针对个体患者的治疗方案定制成为可能。在努力理解肿瘤疾病的分子机制和模式方面,动物模型仍然是不可替代的。已经证明,特别是扩散加权(DW)序列能够以高灵敏度且以非侵入性方式区分常规和创新性化学疗法和免疫疗法的反应者与非反应者。定制疗法的能力是理想的,因为这将使疾病的早期检测和针对个体患者的治疗方案定制成为可能。在努力理解肿瘤疾病的分子机制和模式方面,动物模型仍然是不可替代的。已经证明,特别是扩散加权(DW)序列能够以高灵敏度且以非侵入性方式区分常规和创新性化学疗法和免疫疗法的反应者与非反应者。定制疗法的能力是理想的,因为这将使疾病的早期检测和针对个体患者的治疗方案定制成为可能。在努力理解肿瘤疾病的分子机制和模式方面,动物模型仍然是不可替代的。因为这将有助于及早发现疾病并根据患者的具体情况调整治疗方案。在努力理解肿瘤疾病的分子机制和模式方面,动物模型仍然是不可替代的。因为这将有助于及早发现疾病并根据患者的具体情况调整治疗方案。在努力理解肿瘤疾病的分子机制和模式方面,动物模型仍然是不可替代的。
更新日期:2019-11-01
down
wechat
bug